Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Effects of Sacubitril/Valsartan in Heart Failure
NCT03553303Phase 4Unknown
- Sponsor
- Oslo University Hospital
- Start
- Oct 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan, sponsored by Oslo University Hospital. Primary endpoint: Neurohormonal plasma concentration at 8 weeks. Status: unknown.
02
Drugs
sacubitril + valsartan
Beyond the preview
Go deeper on NCT03553303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553303.